Comparison of CA19-9 with Other Tumor Markers in the Diagnosis of Cancer of the Pancreas
- 1 November 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 9 (6) , 720-724
- https://doi.org/10.1097/00006676-199411000-00008
Abstract
The carbohydrate antigen 19-9 (CA19-9) and radioimmunoassay have been shown to offer new hope for improving the diagnosis of pancreatic cancer, and various tumor markers (including SPan-1, DUPAN-2, and CA50) have been established. While clinical studies of these markers have found satisfactory sensitivities, only a few studies have compared these tumor markers on the same blood samples. We therefore evaluated the clinical efficacy of SPan-1, CA19-9, DUPAN-2, CA50, carcino-embryonic antigen, and Elastase 1 in detecting pancreatic cancer in identical blood samples.Keywords
This publication has 0 references indexed in Scilit: